Trial Evaluating Efficacy and Safety of Bevacizumab (Avastin®/Zeribev®) in Patients With COVID-19 Infection, Nested in the Corimmuno-19 Cohort

Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients CORIMUNO-19- BEVA Trial

Bevacizumab, ZERIBEV® (Pfizer)/AVASTIN® (Roche) 25 mg/ml ®, is a recombinant humanised monoclonal IgG1 antibody It seems interesting to use bevacizumab in severe patients infected with SARS-CoV-2 requiring hospitalization in conventional unit or in ICU.

This protocol CORIMUNO19-BEVA will evaluate the efficacy and safety of AVASTIN®/ ZERIBEV® (bevacizumab) COVID-19 patients hospitalized in conventional units.

This phase 2 randomized clinical trial aimed at evaluating the efficacy and safety of AVASTIN®/ ZERIBEV® (bevacizumab) alone versus standard of care (SoC) in patients hospitalized in conventional units.

Inclusion Criteria:

• Patients Requiring more than 3L/min of oxygen
• WHO progression scale = 5 to 8

Exclusion Criteria:

• Patients in 9 WHO progression class
• Patients with exclusion criteria to the CORIMUNO-19 cohort.
• Hypersensitivity to Bevacizumab or to any of their excipients.
• Pregnancy
• Active Cancer with undergoing treatment
• Oxygen patient requiring long-term oxygen before hospitalization
• Patient already included in a therapeutic trial; however, inclusion should be discussed case by case with the trial coordinator.
• Contraindication to bevacizumab, risk of bleeding especially hemoptysis, active venous or arterial thromboembolic disease and recent surgery.
• Hypersensitivity to the active substance or one of the excipients